Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)

NCT01739348 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT01739348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01739348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2/3
Overall status
Terminated
Start date
November 30, 2012
Completion date
April 14, 2017
Enrollment
2,211 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease